Researchers at F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have synthesized benzimidazole derivatives acting as serine/threonine-protein kinase SIK2 (QIK) and/or SIK1 (SNF1LK) and/or SIK3 (QSK) inhibitors reported to be useful for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, nonalcoholic steatohepatitis, primary sclerosing cholangitis, inflammatory bowel disease, atherosclerosis, type 2 diabetes and glomerulonephritis, among others.
Researchers working at the Lady Davis Institute, Jewish General Hospital, McGill University, have combined whole-exome sequencing (WES) from nearly 300,000 samples from the multiancestry UK Biobank, with ultrasound-derived heel estimated bone mineral density (eBMD) and genome-wide association (GWAS) data to identify potential future therapeutic targets for patients with osteoporosis.
Cgenetech (Suzhou, China) Co. Ltd. has divulged cyclopropanamide-containing compounds acting as Janus kinase (JAK) inhibitors, particularly JAK2 and/or JAK1 and/or JAK3, reported to be useful for the treatment of rheumatoid arthritis, ulcerative colitis, atopic dermatitis, systemic lupus erythematosus, essential thrombocythemia, polycythemia vera and myelofibrosis.
Diabetes has been associated with increased bone fracture risks, however, the cellular and molecular mechanisms underlying diabetic bone fragility are not clear. In the current study, researchers from the Children's Hospital of Philadelphia presented data from a study that aimed to investigate these mechanisms in murine monogenic model of type 1 diabetes (T1D).
Innovo Therapeutics Inc. has prepared and tested new isoindolinone derivative compounds characterized as caspase-1 (IL-1β-converting enzyme), interleukin-1β (IL1B; IL-1β) and apoptosis inhibitors reported to be useful for the treatment of osteoarthritis and pain.
Non-profit Solve GNE LLC has raised over $2.5 million and announced sponsored research agreements to help advance research in hereditary inclusion body myopathy (HIBM), or GNE myopathy (GNEM).
Sarcopenia is the loss of muscle mass typically in the elderly that ultimately reduces mobility, diminishes quality of life, and can cause potential fall-related injuries that can become serious. While exercise is an appropriate approach, unfortunately patients with underlying health conditions and low motivation are unlikely to adhere to regimented muscle training. Moreover, there are no available effective cures for addressing age-related muscle loss. Still, it is possible that a failure to repair muscle after injury may be a major contributor to muscle mass loss in the aged that can be addressed by using muscle stem cells.
Epibone Inc. has received IND clearance from the FDA to begin testing its engineered allogenic osteochondral graft in humans. Clinical trials are set to open patient recruitment as soon as early next year.
A new study on the interleukin 1 (IL-1) pathway and its involvement in systemic inflammation and autoinflammatory diseases has described a mutation of the IL-1 receptor type 1 (IL-1R1) receptor associated with chronic recurrent multifocal osteomyelitis (CRMO). The variant p.Lys131Glu of this receptor was identified in a patient with CRMO. A peripheral blood mononuclear cell analysis showed an inflammatory event in lymphocytes, especially in monocytes and neutrophils. The research was conducted by a group of scientists at Zhejiang University in China and reported in the July 11, 2023, issue of Immunity.
RSS
